![](/wp-content/uploads/2018/10/xPLZOlqQTYq3WYxWaT90.png)
$599
Sanofi Q2 ’19 Earnings Update
Sanofi hosted its Q2 ’19 earnings call and provided updates to its diabetes business unit including the recent Ph1 initiation for its GLP/GIP/GCG triple agonist (SAR441255). Unsurprisingly, Sanofi did not discuss its recent decision to terminate the Lexicon partnership for sotagliflozin. Below, FENIX provides diabetes-related highlights and insights from the call.